-
Vol. 43, January 2021 - current issue
-
Vol 27, September 2019
-
Vol 26, August 2019
-
Vol 25, July 2019
-
Vol 24, June 2019
-
Vol 23, May 2019
-
Vol 22, April 2019
-
Vol 21, March 2019
-
Vol 20, February 2019
-
Vol 19, January 2019
-
Vol 18, December 2018
-
Vol 17, November 2018
-
Vol 16, October 2018
-
Vol 15, September 2018
-
Vol 14, August 2018
-
Vol 13, July 2018
-
Vol 12, June 2018
-
Vol 11, May 2018
-
Vol 10, April 2018
-
Vol 9, March 2018
-
Vol 8, February 2018
-
Vol 7, January 2018
-
Vol 6 No 12, December 2017
-
Vol 6 No 11, November 2017
-
Vol 6 No 10, October 2017
-
Vol 6 No 9, September 2017
-
Vol 6 No 8, August 2017
-
Vol 6 No 7, July 2017
-
Vol 6 No 6, June 2017
-
Vol 6 No 5, May 2017
-
Vol 6 No 4, April 2017
-
Vol 6 No 3, March 2017
-
Vol 6 No 2, February 2017
-
Vol 6 No 1, January 2017
-
Vol 5 No 12, December 2016
-
Vol 5 No 11, November 2016
-
Vol 5 No 10, October 2016
-
Vol 5 No 9, September 2016
-
Vol 5 No 8, August 2016
-
Vol 5 No 7, July 2016
-
Vol 5 No 6, June 2016
-
Vol 5 No 5, May 2016
-
Vol 5 No 4, April 2016
-
Vol 5 No 3, March 2016
-
Vol 5 No 2, February 2016
-
Vol 5 No 1, January 2016
-
Vol 4 No 12, December 2015
-
Vol 4 No 11, November 2015
-
Vol 4 No 10, October 2015
Cover Story Current Issue

The detrimental effects of sleep loss on glucose tolerance are now well established, and insufficient sleep is a risk factor for the development of type 2 diabetes (T2D). In fact, sleep loss is comparable with other more traditional risk factors that are associated with the development of T2D, such as physical inactivity.
Nicholas J. Saner, Matthew J-C. Lee, Jujiao Kuang, Nathan W. Pitchford, ... Jonathan D. Bartlett
Current Issue
Interaction between magnesium and methylglyoxal in diabetic polyneuropathy and neuronal models
Objective
The lack of effective treatments against diabetic sensorimotor polyneuropathy demands the search for new strategies to combat or prevent the condition. Because reduced magnesium and increased methylglyoxal levels have been implicated in the development of both type 2 diabetes and neuropathic pain, we aimed to assess the putative interplay of both molecules with diabetic sensorimotor polyneuropathy.
Methods
In a cross-sectional study, serum magnesium and plasma methylglyoxal levels were measured in recently diagnosed type 2 diabetes patients with (n = 51) and without (n = 184) diabetic sensorimotor polyneuropathy from the German Diabetes Study baseline cohort. Peripheral nerve function was assessed using nerve conduction velocity and quantitative sensory testing. Human neuroblastoma cells (SH-SY5Y) and mouse dorsal root ganglia cells were used to characterize the neurotoxic effect of methylglyoxal and/or neuroprotective effect of magnesium.
Results
Here, we demonstrate that serum magnesium concentration was reduced in recently diagnosed type 2 diabetes patients with diabetic sensorimotor polyneuropathy and inversely associated with plasma methylglyoxal concentration. Magnesium, methylglyoxal, and, importantly, their interaction were strongly interrelated with methylglyoxal-dependent nerve dysfunction and were predictive of changes in nerve function. Magnesium supplementation prevented methylglyoxal neurotoxicity in differentiated SH-SY5Y neuron-like cells due to reduction of intracellular methylglyoxal formation, while supplementation with the divalent cations zinc and manganese had no effect on methylglyoxal neurotoxicity. Furthermore, the downregulation of mitochondrial activity in mouse dorsal root ganglia cells and consequently the enrichment of triosephosphates, the primary source of methylglyoxal, resulted in neurite degeneration, which was completely prevented through magnesium supplementation.
Conclusions
These multifaceted findings reveal a novel putative pathophysiological pathway of hypomagnesemia-induced carbonyl stress leading to neuronal damage and merit further investigations not only for diabetic sensorimotor polyneuropathy but also other neurodegenerative diseases associated with magnesium deficiency and impaired energy metabolism.
Interaction between magnesium and methylglyoxal in diabetic polyneuropathy and neuronal models
Objective
The lack of effective treatments against diabetic sensorimotor polyneuropathy demands the search for new strategies to combat or prevent the condition. Because reduced magnesium and increased methylglyoxal levels have been implicated in the development of both type 2 diabetes and neuropathic pain, we aimed to assess the putative interplay of both molecules with diabetic sensorimotor polyneuropathy.
Methods
In a cross-sectional study, serum magnesium and plasma methylglyoxal levels were measured in recently diagnosed type 2 diabetes patients with (n = 51) and without (n = 184) diabetic sensorimotor polyneuropathy from the German Diabetes Study baseline cohort. Peripheral nerve function was assessed using nerve conduction velocity and quantitative sensory testing. Human neuroblastoma cells (SH-SY5Y) and mouse dorsal root ganglia cells were used to characterize the neurotoxic effect of methylglyoxal and/or neuroprotective effect of magnesium.
Results
Here, we demonstrate that serum magnesium concentration was reduced in recently diagnosed type 2 diabetes patients with diabetic sensorimotor polyneuropathy and inversely associated with plasma methylglyoxal concentration. Magnesium, methylglyoxal, and, importantly, their interaction were strongly interrelated with methylglyoxal-dependent nerve dysfunction and were predictive of changes in nerve function. Magnesium supplementation prevented methylglyoxal neurotoxicity in differentiated SH-SY5Y neuron-like cells due to reduction of intracellular methylglyoxal formation, while supplementation with the divalent cations zinc and manganese had no effect on methylglyoxal neurotoxicity. Furthermore, the downregulation of mitochondrial activity in mouse dorsal root ganglia cells and consequently the enrichment of triosephosphates, the primary source of methylglyoxal, resulted in neurite degeneration, which was completely prevented through magnesium supplementation.
Conclusions
These multifaceted findings reveal a novel putative pathophysiological pathway of hypomagnesemia-induced carbonyl stress leading to neuronal damage and merit further investigations not only for diabetic sensorimotor polyneuropathy but also other neurodegenerative diseases associated with magnesium deficiency and impaired energy metabolism.
The 60 Second Metabolist
In this section authors briefly report on their work recently published in Molecular Metabolism.
Watch the most recent interviews by clicking the video still.
Here is a video of Vimeo. When the iframes is activated, a connection to Vimeo is established and, if necessary, cookies from Vimeo are also used. For further information on cookies policy click here.
Here is a video of Vimeo. When the iframes is activated, a connection to Vimeo is established and, if necessary, cookies from Vimeo are also used. For further information on cookies policy click here.
Here is a video of Vimeo. When the iframes is activated, a connection to Vimeo is established and, if necessary, cookies from Vimeo are also used. For further information on cookies policy click here.